Market news

Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 106.0% to $0.15 during Wednesday's pre-market session. Connect Biopharma Hldgs (NASDAQ:CNTB) stock increased by 79.43% to $1.78. The market value of

Connect Biopharma Holdings Limited (NASDAQ:CNTB) reported mixed preliminary results on September 15 from its Phase 2 Seabreeze STAT asthma study. Rademikibart produced a numerical 66% reduction in treatment failure over 28 days versus placebo, but the primary endpoint missed statistical significance, with p=0.153. Connect Biopharma Holdings Limited (NASDAQ:CNTB) also reported a lung-function benefit on a […]

Connect Biopharma Holdings (CNTB) has an average rating of buy and mean price target of $6.52, accor

Connect Biopharma reported a statistically significant improvement in lung function in its Phase 2 Seabreeze STAT asthma trial, while a 66% reduction in treatment failures did not reach statistical significance. Key Investor TakeawaysConnect Biopharma (NASDAQ:CNTB) said rademikibart produced a statistically significant 130 mL placebo-adjusted improvement in post-bronchodilator FEV1 at Day 7, with a p-value of 0.

– Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo – –Rademikibart produced a rapid, statistically significant improvement in lung function at Day 7 compared to placebo – – Rademikibart was well tolerated in asthma patients experiencing an acute exacerbation with a low incidence of adverse events– – Data from Seabreeze STAT COPD study of rademikibart will be available later this month after which Connect plans to engage with the U.S. Food and

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 11:30 a.m. ET. The live webcast of the presentation may be accessed v

– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – – Cash runway expected for a period of at least one year from the date of this release – SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care f

Detailed price information for Connect Biopharma Holdings Ltd ADR (CNTB-Q) from The Globe and Mail including charting and trades.

Tipranks Press Release.

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Crohn’s Disease pipeline constitutes 40+ key companies continuously working towards developing 50+ Crohn’s Disease treatment therapies, analysis of Clinical Trials, Therap...